Prometheus Materials
Prometheus Materials delivers sustainable building materials that accelerate the world’s transition to a carbon-negative future. Inspired by biological processes found in nature, the company has developed a technology that uses naturally occurring microalgae to produce a bio-cement that offers an affordable, strong, and durable alternative to carbon-intensive portland cement. When mixed with aggregate, this bio-cement creates a zero-carbon building material with the mechanical, physical, and thermal properties comparable or, in some cases, superior to portland cement-based concrete.
Sector
Industrial Biotech
Strategy
Industrial Biotech
Status
Live
Website
prometheusmaterials.com
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.